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Progression of HCV infection in patients with chronic
kidney disease: Reply
To the Editor:
We thank Dr. Cholongitas and colleagues for their
comments on our recent review in this Journal on
HCV in patients with chronic kidney disease (CKD)
and for highlighting ﬁndings from other groups who
have performed liver biopsies in these patients. As they
note we had suggested in a paper several years ago that
hemodialysis or perhaps uremia may provide some pro-
tective eﬀect against ﬁbrosis development in patients
with HCV infection [1]. As cited in our paper, an inter-
national group of hepatologists and nephrologists has
developed guidelines, under the auspices of the National
Kidney Foundation, to guide the management of pa-
tients with CKD and HCV infection [2]. Prospective
studies with serial liver biopsies are clearly required in
this patient population to further deﬁne the natural his-
tory of HCV infection at various stages of CKD includ-
ing post renal transplantation particularly as treatment
options for HCV expand.
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Hepatitis E virus as an emerging cause of chronic liver disease
in organ transplant recipients
To the Editor:
We read with great interest the very complete and up-
to-date review by R.H. Purcell and S.U. Emerson on
hepatitis E virus (HEV) [1]. It highlights that this virus
is the leading or the second leading cause of acute hep-
atitis in adults in many parts of the developing world,
and that an increasing number of sporadic autochtho-
nous acute hepatitis E cases have been recently reported
in industrialized countries [1]. Unexpectedly, a new clin-
ical feature has just been described in association with
autochthonous hepatitis E virus (HEV) infections in
developed countries [2–4]. Indeed, since February
2008, cases of HEV-related chronic hepatitis have been
reported in organ transplant recipients by three diﬀerent
teams, including ours. This ﬁnding still adds signiﬁcant
interest to hepatitis E, and questions the extent and
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clinical presentation and outcome of chronic HEV infec-
tions. We describe herein a new case of chronic hepatitis
E in an organ transplant recipient, which was associated
with very mild elevation of liver biological tests in con-
trast with previous reports.
A 45-year-old patient who had undergone kidney
transplantation in 1991 and in 2004 presented in Sep-
tember 2006 with increased liver biological tests. Gam-
ma-glutamyltransferases (GGT) level had risen from
42 to 170 IU/L between June 2006 and September
2006, concurrently with a fourfold increase in alanine
amino transferases (ALT) level, from 6 to 35 IU/L
(Fig. 1A). During the following months, GGT levels
progressively decreased while ALT level plateaued at a
signiﬁcantly higher level than before September 2006
(Fig. 1A). Hepatitis C virus (HCV) serology and serum
HCV RNA (Cobas TaqMan assay, Roche Diagnostics,
Meylan, France) were negative. Hepatitis B virus (HBV)
serology showed past immunization and HBV DNA
(Cobas TaqMan assay) was undetectable in serum. No
evidence for auto-immune hepatitis could be found.
Ferritinemia and transferrin saturation were normal.
Alcohol consumption was lower than 10 g/day. No
modiﬁcation of the patient’s therapy could be noted.
Diagnosis of hepatitis E virus (HEV) infection was
established in March 2007 on the basis of IgG and
IgM anti-HEV antibodies positivity (Optical Density
Ratio, 5.4 and 4.3, respectively; Adaltis EIAGen kits,
Adaltis Italia S.p.A., Casalecchio di Reno, Italy) and
HEV RNA detection and sequencing in serum using
in-house assays [5]. Retrospective HEV RNA and anti-
HEV antibody testings that could be performed on ﬁve
available sera collected between November 2002 and
October 2005 were negative. Liver biopsy performed in
August 2007 showed evidence for chronic hepatitis with
periportal inﬂammation, piece-meal necrosis, and ﬁbro-
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Fig. 1(A) Evolution of liver biological markers (ALT, AST, and GGT) and virological markers in serum. HEV RNA remained at stable titers fromMarch
2007 to March 2008. (B and C). Liver biopsy was performed in August 2007 showing mild mononuclear inﬂammation with peace-meal necrosis and
periportal ﬁbrosis (arrows) ((B) haematoxylin and eosin; (C) Reticulin staining. Original magniﬁcation 200). UDCA, ursodeoxychloic acid. [This ﬁgure
appears in colour on the web.]
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sis (Fig. 1B and C). Ursodeoxycholic acid (UDCA) was
introduced in September 2007. Subsequently, liver bio-
logical tests slightly improved. However, HEV RNA re-
mained detectable at stable titres in serum from March
2007 until March 2008. The patient did not report any
recent travel abroad or contacts with travellers. HEV
RNA ORF-2 sequence clustered into genotype 3f, which
is found in autochthonous hepatitis E and in swine in
Europe [1]. Thus, HEV sequences corresponding to the
ten BLAST hits with the highest scores on sequence
from the case reported here were from French and Span-
ish humans or Spanish swine (http://www.ncbi.nlm.nih.
gov/BLAST/).
The present observation fulﬁls the criteria for chronic
hepatitis, consisting in elevation of liver biological tests
and HEV RNA detection lasting more than 6 months, in
association with histological evidence for liver inﬂam-
mation and ﬁbrosis. Eleven cases of chronic HEV infec-
tion have been reported since the review by Purcell and
Emerson on hepatitis E was published in a recent issue
of the Journal of Hepatology. All cases occurred in so-
lid-organ transplant recipients. Transplanted organs
were liver, kidney, and kidney/ pancreas in 5, 4, and
two cases, respectively. This clearly suggests that the
atypical clinical and virological outcome for HEV infec-
tion in these cases could be related to the immunosup-
pressive treatment, which might have resulted in sub-
optimal anti-HEV speciﬁc immune responses and subse-
quent viral persistence. Such a hypothesis has been evo-
cated by Kamar et al. who found signiﬁcantly reduced
CD2-, CD3-, and CD4-lymphocytes counts in patients
in whom chronic disease developed, and it has been re-
cently debated by Schildgen et al. [6] However, the pres-
ent case distinguishes itself from previously reported
chronic hepatitis E. Indeed, the patient did not present
clinical signs for acute hepatitis and ALT level never ex-
ceeded 1.5-fold the upper normal limit (Fig. 1A). Note-
worthy, ALT level returned to normal ranges following
UDCA initiation despite stable HEV RNA titers in ser-
um. In contrast, in previously reported chronic hepatitis
E, ALT levels were nearly ten-fold the upper normal
limit (mean highest ALT level = 276 IU/mL; range,
69–874 IU/mL) [2–4]. Furthermore, HEV-related cir-
rhosis could be found in ﬁve patients, including one in
whom cirrhosis occurred as early as one year following
infection, and two other cases that necessitated liver
transplantation [3,4]. With regards to these severe clini-
cal outcomes, it should be outlined that, in the present
case, liver histology showed only mild hepatitis with
very early ﬁbrosis. Therefore, although a longer fol-
low-up is mandatory to conﬁrm this issue, the present
observation suggests that chronic HEV infection may
also result in mild chronic hepatitis with low activity
and almost normal biological liver tests.
Altogether, these data deserve further studies to as-
sess the actual incidence, prevalence and outcome of
chronic HEV infection in organ transplant recipients
and warrants for including HEV testing in diagnosis
investigation in transplanted patients presenting with
mild chronic elevation of liver biological tests.
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